Carmat To Launch Total Artificial Heart In Early 2021
Executive Summary
After years of setbacks, the company will launch its device in Europe as a bridge to transplant in heart failure patents.
You may also be interested in...
Pivotal Trial Of Carmat’s Total Artificial Heart Delayed
Carmat suspended the production of its Total Artificial Heart while it strengthens certain manufacturing processes.
FDA Updates Class I Recall Alert For SynCardia's Bridge-To-Transplant System
SynCardia Systems' Freedom Driver System was subject to a class I recall last year, and now US FDA has updated its concerns about a component of the firm's Temporary Total Artificial Heart based on post-approval study data, and is asking that malfunctioning drivers be returned to the manufacturer.
INTERVIEW: Carmat stays on the beat with potential 2016 artificial heart CE mark
Carmat has taken another step towards approval of its biocompatible artificial heart after developing a portable console that has allowed one patient implanted with the system to return home.